Highlights on selpercatinib in RET-mutant medullary thyroid cancer: The LIBRETTO-531 study

Dr Julien Hadoux reports on key results from ESMO Congress 2023 on LBA3 – Randomized Phase 3 Study of Selpercatinib versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer

Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org

Take the opportunity to connect and share this video with your friends and family if you find it useful.